Latest / Community Health Media
Dr. Anne O'Dea & Dr. Mabel Mardones - SERENA-6 & ctDNA-Guided Therapy in mBC
Can we improve outcomes by changing treatment before radiographic progression occurs?
In this in-depth discussion, Dr. Anne O'Dea and Dr. Mabel Mardones explore how the SERENA-6 trial is reshaping the management of HR-positive, HER2-negative metastatic breast cancer through ctDNA-guided treatment decisions and earlier intervention for emerging ESR1 mutations.
Topics discussed include:
The clinical impact of the SERENA-6 trial
Using ctDNA to detect ESR1 mutations before disease progression
When and why to switch endocrine therapy
Camizestrant and molecularly guided treatment strategies…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.